Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Article in Journal of Nuclear Medicine (April 2024)
The most recent citing publications are shown below. View all 60 publications that cite this research output on Dimensions.
Article in Journal of Nuclear Medicine (April 2024)
Article in Journal of Chemotherapy (February 2024)
Article in Clinical and Translational Imaging (July 2023)